FILE PHOTO: A tablet of Avigan (generic name: Favipiravir), a drug developed as an anti-influenza treatment by a subsidiary of Fujifilm Holdings, is displayed during a photo opportunity at Fujifilm's headquarters in Tokyo, Oct. 22, 2014. REUTERS/Issei Kato
TOKYO (Reuters) - Research into Fujifilm Holdings Corp's Avigan will continue into June, Japan's government said on Tuesday, effectively dashing hopes by Prime Minister Shinzo Abe that the drug would be approved as a COVID-19 treatment this month.
Abe had said he hoped the drug would be approved in May if its efficacy and safety could be confirmed.
Already a subscriber? Log in.
Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
